Funding Opportunity PAR-21-133 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs, or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase II studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drugs impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.

Notice NOT-MH-21-090 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-070 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-069 from the NIH Guide for Grants and Contracts

Notice NOT-HG-21-023 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-066 from the NIH Guide for Grants and Contracts

Notice NOT-GM-21-021 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-045 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-22-010 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to develop technologies to improve the delivery of pharmacological, gene editing, or other cargoes for HIV and SUD mechanistic research.

Notice NOT-GM-21-028 from the NIH Guide for Grants and Contracts

Notice NOT-GM-21-027 from the NIH Guide for Grants and Contracts

Notice NOT-GM-21-030 from the NIH Guide for Grants and Contracts

Notice NOT-GM-21-025 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-016 from the NIH Guide for Grants and Contracts

Notice NOT-DA-21-007 from the NIH Guide for Grants and Contracts

Notice NOT-TR-21-022 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-156 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit an application for the next 6-year cycle of the Midlife in the United States (MIDUS) Study. The goals of this next phase are to complete the fourth wave of longitudinal data collection for the core MIDUS sample and the second wave of the MIDUS refresher sample.

Funding Opportunity PAR-21-157 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit an Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD)-focused U01 that is ancillary to, but integrated with, the Midlife in the United States Study (MIDUS) U19 to provide in-depth information to elucidate behavioral, social, psychological and biological pathways of risk and resilience to cognitive decline and AD/ADRD.

Notice NOT-GM-21-023 from the NIH Guide for Grants and Contracts

Notice NOT-GM-21-024 from the NIH Guide for Grants and Contracts